MAPT and Alzheimer disease: In the current meta-analysis, SNP rs3785883 was found not to be associated with AD risk under all the genetic models; in AD cases, however, there was higher levels of Total tau mRNA in those individuals who carry rs3785883 minor allele (AA or AG) than those with non-carriers (GG) with evidence of beta-amyloid deposition [24], suggesting that SNP rs3785883, which changes the expression of the marker protein of AD, but is not associated with AD risk, might be an complicated SNP of the MAPT gene.